1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Breast Cancer: KOL Insight

Breast Cancer: KOL Insight

  • May 2015
  • ID: 3090967
  • Format: PDF
  • Firstword Pharma


Table of Contents

How will breast cancer be treated in the years ahead – and what targeted therapies represent the greatest potential in terms of transforming disease therapy?

KOL Insight: Breast Cancer provides a comprehensive qualitative review of marketed and pipeline therapies in the breast cancer market with an emphasis on current and future treatment pathways. Interviews with 12 Key Opinion Leaders from the US and Europe add future-facing perspective and insights to the data.

This report includes key insights on the characterisation of optimal sequencing for HER2-positive breast cancer and how this might change, as well as the potential for new therapies for HER2-negative/HR-positive breast cancer and triple-negative breast cancer which may alter the treatment paradigm. The introduction of new CDK inhibitors, as well as the potential approval of PARP inhibitors in the future, are set to change the way the disease is treated.

Key Benefits

Better understand how your product is perceived, or likely to be perceived, by the marketplace
Learn about the strengths and weaknesses of your competitors
Understand different approaches to positioning that will put your product in the most favorable light possible
Understand where the opportunities and threats are in the marketplace
Gain insights required to better direct your sales and/or marketing teams toward success

Answers to Critical Questions

Which drug is the treatment of choice for each patient segment, and what product attributes shape preference?

Which clinical trials have the greatest potential to impact prescribing trends?

How will the use of each product evolve in the future in terms of line of therapy and preference?

How will the treatment landscape evolve in the future for each patient segment and line of therapy?

What are the experts’ greatest concerns about new and future therapies?

Pipeline Therapies Covered

AbbVie veliparib (ABT 888)
AstraZeneca olaparib (Lynparza)
BioMarin Pharmaceutical talazoparib (BMN 673)
Boehringer Ingelheim Gilotrif (afatinib)
Eli Lilly abemaciclib (LY 2835219)
Galena Biopharma NeuVax (nelipepimut-S)
Merck & Co./Tesaro niraparib (MK 4827)
Novartis/Astex ribociclib (LEE 011)
Novartis buparlisib (BKM 120)
Puma Biotechnology neratinib
Roche/Genentech taselisib (GDC 0032)
Syndax Pharmaceuticals entinostat (SNDX 275)

Marketed Drugs Covered

Genentech/Roche/Chugai Herceptin (trastuzumab)
Genentech/Roche/Chugai Kadcyla (ado-trastuzumab emtansine)
Genentech/Roche/Chugai Perjeta (pertuzumab)
GlaxoSmithKline/Nippon Kayaku Tykerb (lapatanib)
Novartis Afinitor (everolimus)
Pfizer Ibrance (palbociclib)

Report Features
Comprehensive commercial and clinical profiles of each targeted therapy currently in market
Summaries and analyses of all significant clinical trials now underway
Overviews of current treatment algorithms based on patient segment, line of therapy, and patient characteristics
The opinions and insights of a dozen KOLs, split equally between the US and Europe
Summaries and analyses of current and future treatment pathways

Key Opinion Leaders

North America

Dr. Adam M. Brufsky, MD, PhD, Professor of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

Dr. Richard Finn, MD, Assistant Professor of Medicine, Geffen School of Medicine at UCLA, Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA

Dr. Reshma Mahtani, DO, Assistant Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL

Dr. Erica L. Mayer, MD MPH, Senior Physician, Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute, Boston, MA; Assistant Professor in Medicine, Harvard Medical School, Boston, MA

Dr. Joyce O’Shaughnessy, MD, Co-Chair of Breast Cancer Research, Baylor-Charles A. Sammons Cancer Center, Dallas, TX

Dr. Charles Vogel, MD, Professor of Clinical Medicine, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL


Dr. Thomas Bachelot, MD, Head, Breast Cancer Unit and the Clinical Trial Unit, Centre Leon Berard, Lyon, France
Dr. Adrian L. Harris, MD, DPhil, Professor of Medical Oncology, University of Oxford; Director, Cancer Research UK Medical Oncology Unit
Dr. Chris Twelves, Professor of Clinical Cancer Pharmacology and Oncology and Head of Section of Oncology and Clinical Research, Leeds Cancer Research UK Centre, Leeds, UK
Dr. Etienne GC Brain, MD PhD, Medical Oncologist, Hôpital René Huguenin, Saint-Cloud, France
Dr. Véronique Diéras, MD, Head, Department of Clinical Research and Chief of the Clinical Investigational Unit, Institut Curie, Paris, France and Saint Cloud, France
Dr. Rafael Trujillo Vilchez, Medical Oncologist, Xanit International Hospital, Malaga, Spain

Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, May 2015.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Oncology Drugs Market Research Report by Indication, by Drug Class Type, by Distribution - United States Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 2249
  • January 2021
  • 77 pages

Oncology Drugs Market Research Report by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Esophagus Cancer), by Drug Class Type (Chemotherapy, Hormonal Therapy, Immunotherapy, ...

  • United States
  • Infectious Disease
  • Bladder Cancer
  • Industry analysis

Global Sarcoma Drugs Industry $ 5600 April 2021


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on